1.24
price up icon5.98%   0.07
pre-market  Pre-market:  1.13   -0.11   -8.87%
loading
Cabaletta Bio Inc stock is traded at $1.24, with a volume of 1.36M. It is up +5.98% in the last 24 hours and down -31.30% over the past month.
See More
Previous Close:
$1.17
Open:
$1.18
24h Volume:
1.36M
Relative Volume:
1.15
Market Cap:
$57.19M
Revenue:
-
Net Income/Loss:
$-67.68M
P/E Ratio:
-0.747
EPS:
-1.66
Net Cash Flow:
$-54.24M
1W Performance:
-21.02%
1M Performance:
-31.30%
6M Performance:
-73.10%
1Y Performance:
-92.48%
1-Day Range:
Value
$1.16
$1.27
1-Week Range:
Value
$1.155
$1.68
52-Week Range:
Value
$1.155
$19.04

Cabaletta Bio Inc Stock (CABA) Company Profile

Name
Name
Cabaletta Bio Inc
Name
Phone
(267) 759-3100
Name
Address
2929 ARCH STREET, PHILADELPHIA, PA
Name
Employee
0
Name
Twitter
@CabalettaBio
Name
Next Earnings Date
2025-03-31
Name
Latest SEC Filings
Name
CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CABA
Cabaletta Bio Inc
1.24 57.19M 0 -67.68M -54.24M -1.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-20-24 Downgrade Evercore ISI Outperform → In-line
Dec-19-24 Downgrade Wells Fargo Overweight → Equal Weight
Oct-10-24 Initiated UBS Buy
Feb-05-24 Initiated Jefferies Buy
Nov-29-23 Initiated William Blair Outperform
Oct-24-23 Initiated Cantor Fitzgerald Overweight
Oct-19-23 Initiated Stifel Buy
Sep-05-23 Initiated Citigroup Buy
Jul-18-23 Initiated Guggenheim Buy
Jan-27-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Aug-30-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-08-21 Initiated Wells Fargo Overweight
Oct-19-21 Resumed Morgan Stanley Overweight
Jun-30-21 Initiated Mizuho Buy
Jan-08-21 Initiated Chardan Capital Markets Buy
Oct-13-20 Initiated H.C. Wainwright Buy
Nov-19-19 Initiated Cowen Outperform
Nov-19-19 Initiated Evercore ISI Outperform
Nov-19-19 Initiated Morgan Stanley Overweight
View All

Cabaletta Bio Inc Stock (CABA) Latest News

pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Receives Buy Rating from Guggenheim - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Cut to $22.00 by Analysts at Morgan Stanley - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Posts Earnings Results, Meets Expectations - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Releases Earnings Results, Meets Estimates - MarketBeat

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio Reports Strong Clinical Progress and Q4 2024 Financial Results - MSN

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Sells 16,585 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Price Target Lowered to $7.00 at UBS Group - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio (NASDAQ:CABA) Given New $3.00 Price Target at Wells Fargo & Company - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Cabaletta Bio Advances T Cell Therapies for Autoimmune Diseases - TipRanks

Apr 02, 2025
pulisher
Apr 01, 2025

Cabaletta Bio’s Strategic Advances in Myositis Treatment Drive Buy Rating - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating By Investing.com - Investing.com South Africa

Apr 01, 2025
pulisher
Apr 01, 2025

UBS cuts Cabaletta Bio stock target to $7, maintains Buy rating - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Is Cabaletta Bio Inc (CABA) worth investing in despite its undervalued state? - uspostnews.com

Apr 01, 2025
pulisher
Apr 01, 2025

UBS Adjusts Price Target on Cabaletta Bio to $7 From $10, Keeps Buy Rating - MarketScreener

Apr 01, 2025
pulisher
Apr 01, 2025

Cabaletta Bio price target lowered to $22 from $30 at Morgan Stanley - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy By Investing.com - Investing.com Canada

Apr 01, 2025
pulisher
Mar 31, 2025

Stifel cuts Cabaletta Bio stock target to $13, maintains buy - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

BIT Capital GmbH Invests $431,000 in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio, Inc. SEC 10-K Report - TradingView

Mar 31, 2025
pulisher
Mar 31, 2025

Cabaletta Bio Reports Clinical Wins in Multiple Diseases, Maintains Strong Cash Position - Stock Titan

Mar 31, 2025
pulisher
Mar 29, 2025

Bank of New York Mellon Corp Sells 16,945 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Mar 29, 2025
pulisher
Mar 26, 2025

Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Cabaletta Bio stock hits 52-week low at $1.59 amid sharp decline - Investing.com Australia

Mar 26, 2025
pulisher
Mar 24, 2025

Are Value Hunters Buying Cabaletta Bio Inc (NASDAQ: CABA) Stock? - Stocks Register

Mar 24, 2025
pulisher
Mar 22, 2025

Head-To-Head Comparison: Cabaletta Bio (NASDAQ:CABA) vs. Outlook Therapeutics (NASDAQ:OTLK) - Defense World

Mar 22, 2025
pulisher
Mar 22, 2025

Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat

Mar 22, 2025
pulisher
Mar 20, 2025

Cellares and Cabaletta Bio Complete Manufacturing Technology Adoption Program - Genetic Engineering and Biotechnology News

Mar 20, 2025
pulisher
Mar 19, 2025

Cellares and Cabaletta Bio Successfully Complete Manufacturing Technology Adoption Program for Rese-cel Using the Cell Shuttle™ Platform - Business Wire

Mar 19, 2025
pulisher
Mar 17, 2025

Cabaletta Bio Inc expected to post a loss of 64 cents a shareEarnings Preview - TradingView

Mar 17, 2025
pulisher
Mar 16, 2025

Cabaletta Bio (CABA) to Release Quarterly Earnings on Thursday - MarketBeat

Mar 16, 2025
pulisher
Mar 16, 2025

Analysts Set Cabaletta Bio, Inc. (NASDAQ:CABA) Price Target at $22.71 - MarketBeat

Mar 16, 2025
pulisher
Mar 12, 2025

Brokerages Set Cabaletta Bio, Inc. (NASDAQ:CABA) Target Price at $22.71 - MarketBeat

Mar 12, 2025
pulisher
Mar 09, 2025

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Mar 09, 2025
pulisher
Mar 06, 2025

Head-To-Head Contrast: Cabaletta Bio (NASDAQ:CABA) & Cidara Therapeutics (NASDAQ:CDTX) - Defense World

Mar 06, 2025
pulisher
Mar 02, 2025

Cabaletta Bio to Present at TD Cowen 45th Annual Health Care Conference - MSN

Mar 02, 2025
pulisher
Mar 01, 2025

Cabaletta Bio stock hits 52-week low at $1.75 amid sharp decline - Investing.com Australia

Mar 01, 2025

Cabaletta Bio Inc Stock (CABA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
Cap:     |  Volume (24h):